[1]WANG Y J,MENG X,WANG A X,et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA[J]. N Engl J Med,2021,385(27):2520-2530.
[2]WANG Y J,WANG Y L,ZHAO X Q,et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack[J]. N Engl J Med,2013,369(1):11-19.
[3]CAST Collaborative Group. CAST:randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke[J]. Lancet,1997,349(9066):1641-1649.
[4]International Stroke Trial Collaborative Group. The international stroke trial(IST):a randomised trial of aspirin,subcutaneous heparin,both,or neither among 19 435 patients with acute ischaemic stroke[J]. Lancet,1997,349(9065):1569-1581.
[5]WANG Y J,PAN Y S,ZHAO X Q,et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack(CHANCE)trial:one-year outcomes[J]. Circulation,2015,132(1):40-46.
[6]WONG K S,WANG Y L,LENG X Y,et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack:an updated systematic review and meta-analysis[J]. Circulation,2013,128(15):1656-1666.
[7]PAN Y S,CHEN W Q,XU Y,et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack:a systematic review and meta-analysis[J]. Circulation,2017,135(1):21-33.
[8]WANG Y L,ZHAO X Q,LIN J X,et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JAMA,2016,316(1):70-78.
[9]PAN Y S,CHEN W Q,WANG Y L,et al. Association between ABCB1 polymorphisms and outcomes of clopidogrel treatment in patients with minor stroke or transient ischemic attack:secondary analysis of a randomized clinical trial[J]. JAMA neurology,2019,76(5):552-560.
[10]WANG Y L,CHEN W Q,LIN Y,et al. Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack:open label,blinded endpoint,randomised controlled phase Ⅱ trial[J/OL]. BMJ,2019,365:l2211[2022-05-19]. https://doi. org/10.1136/bmj.l2211.
[11]MENG X,WANG A X,ZHANG G J,et al. Analytical validation of GMEX rapid point-of-care CYP2C19 genotyping system for the CHANCE-2 trial[J]. Stroke Vasc Neurol,2021,6(2):274-279.